Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19

Overview of attention for article published in JAMA: Journal of the American Medical Association, December 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 16 news outlets
blogs: 3 blogs
twitter: 153 X users

facebook: 1 Facebook page
reddit: 1 Redditor
podcasts: 1 podcast

Readers on

mendeley: 30 Mendeley

So far, Altmetric has seen 160 X posts from 153 X users, with an upper bound of 1,532,304 followers.

RT @AcrossTheMersey: @LenkaB99 @atranscendedman Please see from Mike Hoerger below. This drug has raised several flags and personally speak…

@LenkaB99 @atranscendedman Please see from Mike Hoerger below. This drug has raised several flags and personally speaking, I’d consider it a dangerous, nightmare experience.

@DrToddLee @PaulSaxMD https://t.co/hj6fhfoOEh A secondary composite outcome of death or health care use (including urgent care or emergency department visits or hospitalizations) suggested one-third fewer events in the fluvoxamine group compared with p…

@adamcifu https://t.co/XJThRFA9Oh.

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 156 additional X posts.